Press Release

AI in Drug Discovery Market to Grow with a CAGR of 10.18% through 2028

Increasing adoption of AI in pharmaceutical industry and rise in incidence of chronic disease is expected to drive the Global AI in Drug Discovery Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “AI in Drug Discovery Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F”, the Global AI in Drug Discovery Market stood at USD 750.04 Million in 2022 and is anticipated to grow with a CAGR of 10.18% in the forecast period, 2024-2028. The increasing demand for the discovery and development of novel drug therapies, coupled with the expanding manufacturing capacities of the life science industry, is driving the need for artificial intelligence (AI)-empowered solutions in drug discovery processes. Manufacturers in the life science sector prioritize replenishing their product pipelines as many top-selling drugs go off patent.

Moreover, the market is driven by a growing number of public-private partnerships that foster the adoption of AI-powered solutions in drug discovery and development. Dominating the clinical trial space are countries such as France, the U.S., Spain, and Japan, while the U.K. focuses on enhancing research and development activities. Drug discovery and development is a complex and time-consuming process that incurs substantial costs. Industry journals report average costs of USD 2.6 billion and a timeline of over 10 years for discovering and developing new drug therapies.

Due to the narrow development testing funnel, most candidate therapies are eliminated during the initial phases of clinical trials, particularly preclinical and phase-1 trials. This contributes directly to the high costs and lengthy timelines involved in the process. The adoption of AI solutions in the clinical trial process has the potential to eliminate obstacles, reduce cycle time, and enhance the productivity and accuracy of clinical trials. As a result, the life science industry stakeholders are increasingly embracing these advanced AI solutions in drug discovery processes. According to data from Clinical Trials Arena, the number of strategic collaborations and partnerships between major AI-based drug discovery companies and pharmaceutical firms increased from four partnerships in 2015 to 27 partnerships in 2020.

Digitalization in biomedical and clinical research spaces is paving the way for the implementation of AI solutions. The vast array of datasets generated from drug discovery processes, such as molecule screening and preclinical studies, is driving the adoption of AI-powered solutions. These extensive datasets pose challenges for researchers to accurately analyze studies, but with the implementation of AI solutions, screening processes can be accelerated and turnaround times reduced. Additionally, the ongoing Covid-19 pandemic has significantly transformed the perception of clinical trials and increased the utilization of AI solutions. Notably, renowned pharmaceutical companies like Pfizer, Novartis, Bayer, Sanofi, and Johnson & Johnson are collaborating with AI-based drug discovery solution providers. The availability of various options, such as data mining and personalization capabilities, is driving the adoption of AI solutions in drug discovery processes. Furthermore, the integration of deep learning and machine learning algorithms in AI platforms enhances accuracy in identifying molecule binding properties of drugs.

Moreover, the incorporation of advanced technologies like electronic data capture (EDC) supports manufacturers in improving patient data management and reducing monitoring costs. Integration of electronic Clinical Outcome Assessment (e-COA) in AI solutions helps minimize process errors. Recently, advanced analytics have been integrated into these AI solutions, aiding stakeholders in data mining, patient recruitment, and medical and clinical records management.

Among the different phases of a clinical trial study, preclinical testing incurs the highest revenue loss with low returns. By adopting AI solutions, the preclinical testing phase can be optimized to minimize costs. AI-based models accurately analyze human physiological responses and eliminate experimental costs. Stringent regulations pertaining to clinical trial studies set by regulatory authorities worldwide are expected to drive the demand for AI solutions in drug discovery processes.

Moreover, government authorities in developed and emerging economies are undertaking favorable initiatives to increase the adoption of AI solutions and the number of clinical trials.


Browse over 26 market data Figures spread through 91 Pages and an in-depth TOC on "Global AI in Drug Discovery Market.”


The Global AI in Drug Discovery Market is segmented into component type, drug type, application type, therapeutic area, regional distribution, and company.

Based on application type, the drug optimization and repurposing application type segment accounted for the largest revenue share in 2022. AI platforms facilitate the identification of target proteins for drug discovery, enabling the assessment of adverse events and potential side effects. Through drug repurposing, molecules can be optimized to enhance efficacy while minimizing side effects. AI platforms also expedite the study and modification of a company's drug portfolio, expediting the development of new drugs.

Based on region, North America segment is expected to grow during the forecast period. North America held the largest revenue share in 2022, establishing itself as a forerunner in AI technology. IBM's supercomputer, 'Watson', gained recognition by winning the trivia game 'Jeopardy', leading to further advancements in the field of AI. Since then, AI has become an integral part of the tech industry, with significant applications in sectors such as pharmaceuticals. Major tech giants in the United States have collaborated with prestigious institutes to accelerate drug discovery, design, and repurposing. Additionally, AI is being utilized to study diseases and derive meaningful conclusions, ultimately improving disease management. The APAC market is expected to exhibit the fastest CAGR from 2023 to 2028. Developing countries in the Asia Pacific region are embracing AI as a tool for understanding diseases and facilitating drug discovery. Notably, Intuition Systems, an Indian AI company, has partnered with Lantern Pharma to enhance drug discovery and biomarker identification. Niramai and Sigtuple are other AI companies dedicated to leveraging advanced technologies to improve healthcare through faster drug discovery and more accurate identification of target proteins and biomarkers.


Major companies operating in Global AI in Drug Discovery Market are:

  • GNS Healthcare
  • BioSymetrics
  • BPGbio, Inc.
  • Atomwise Inc.
  • Owkin Inc.
  • NVIDIA Corporation
  • IBM Corporation
  • Microsoft Corporation
  • Aria Pharmaceuticals, Inc.
  • Insilico Medicine Inc.


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The pharmaceutical industry has traditionally been slow in adopting new technologies such as AI. However, there has been a noticeable surge in activity in recent years. Numerous companies, including established leaders, are now incorporating AI into their digital transformation strategies. AI is poised to become a pivotal driver of healthcare innovation, with applications ranging from managing chronic diseases and drug discovery to improving clinical trials, manufacturing, and supply chains. The integration of artificial intelligence (AI) is expected to yield lucrative opportunities in the healthcare industry. By reducing the research and development gap in drug manufacturing and enabling targeted drug production, AI is empowering biopharmaceutical companies to enhance their market share. This significant factor is fueling the growth of the global AI for drug discovery market. Moreover, the mounting pressure on drug manufacturers to lower drug prices is another key factor expected to propel the expansion of the global AI for drug discovery market. Additionally, the scarcity of skilled healthcare personnel is anticipated to further accelerate the growth of the global AI for drug discovery market.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“AI in Drug Discovery Market Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Component Type (Software and Services), By Drug Type (Small Molecule and Large Molecule), By Application Type (Preclinical Testing, Drug Optimization, and Repurposing, Target Identification, Candidate Screening, and Others), By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Rare Diseases, and Others), By Region and Competition”, has evaluated the future growth potential of Global AI in Drug Discovery Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global AI in Drug Discovery Market.


Contact

TechSci Research LLC

420 Lexington Avenue,

Suite 300, New York,

United States- 10170

M: +13322586602

Email: [email protected]

Website: https://www.techsciresearch.com

Relevant News